文献速递消化系统肿瘤

帕妥珠单抗联合曲妥珠单抗治疗HER2扩增的转移性结直肠癌(MyPathway):一项多中心、开放标签、2a期多篮子研究的更新报告

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
PubMed 文献 · Lancet Oncol · 2019-03-08

MyPathway是一项2a期多篮子研究,评估帕妥珠单抗联合曲妥珠单抗在HER2扩增的难治性转移性结直肠癌患者中的活性。57例可评估患者中,客观缓解率为32%(95%CI 20-45),其中完全缓解1例(2%),部分缓解17例(30%)。联合治疗耐受性良好,最常见不良事件为腹泻、疲劳和恶心;3-4级治疗相关不良事件发生率为37%,无治疗相关死亡。

要点

  • 帕妥珠单抗联合曲妥珠单抗在HER2扩增的难治性转移性结直肠癌中客观缓解率为32%(95%CI 20-45)。
  • 57例患者中完全缓解1例(2%),部分缓解17例(30%)。
  • 3-4级治疗相关不良事件发生率为37%,无治疗相关死亡。

核心结论

  • 帕妥珠单抗联合曲妥珠单抗双靶向治疗耐受性良好,可能为经重度治疗的HER2扩增转移性结直肠癌患者提供治疗机会。

研究设计与样本

  • MyPathway是一项正在进行中的2a期多篮子研究,本亚组分析纳入57例来自美国16个州25家医院或诊所的HER2扩增转移性结直肠癌患者。
  • 纳入标准为年龄18岁及以上、组织学确诊的难治性HER2扩增转移性结直肠癌、具有可测量或可评估病灶、ECOG体能状态评分≤2。
  • 患者接受帕妥珠单抗(840 mg负荷剂量,随后420 mg每3周静脉给药)联合曲妥珠单抗(8 mg/kg负荷剂量,随后6 mg/kg每3周静脉给药)。
  • 主要终点为研究者报告的客观缓解率,分析按方案进行。

主要发现

  • 2014年10月20日至2017年6月22日期间,共57例HER2扩增转移性结直肠癌患者入组并被认定符合本队列分析纳入标准。
  • 截至2017年8月1日,57例可评估患者中1例(2%)达完全缓解,17例(30%)达部分缓解,总计18例(32%,95%CI 20-45)达客观缓解。
  • 最常见的治疗相关不良事件为腹泻(19/57例,33%)、疲劳(18/57例,32%)和恶心(17/57例,30%)。
  • 3-4级治疗相关不良事件发生于21/57例(37%),最常见为低钾血症和腹痛(各3/57例,5%)。
  • 严重治疗相关不良事件报告于10例(18%)患者,其中2例(4%)事件(寒战和输注相关反应)被认为与治疗相关;无治疗相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer. MyPathway evaluates the activity of targeted therapies in non-indicated tumour types with potentially predictive molecular alterations. We aimed to assess the activity of pertuzumab and trastuzumab in patients with HER2-amplified metastatic colorectal cancer. METHODS: MyPathway is an ongoing, phase 2a, multiple basket study. Patients in this subset analysis were aged 18 years or older and had treatment-refractory, histologically confirmed HER2-amplified metastatic colorectal cancer with measurable or evaluable disease and an Eastern Cooperative Oncology Group performance status score of 2 or less, enrolled from 25 hospitals or clinics in 16 states of the USA. Patients received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks, intravenously) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, intravenously). The primary endpoint was the proportion of patients who achieved an objective response based on investigator-reported tumour responses. Analyses were done per protocol. This ongoing trial is registered with ClinicalTrials.gov, number NCT02091141. FINDINGS: Between Oct 20, 2014, and June 22, 2017, 57 patients with HER2-amplified metastatic colorectal cancer were enrolled in the MyPathway study and deemed eligible for inclusionin this cohort analysis. Among these 57 evaluable patients, as of Aug 1, 2017, one (2%) patient had a complete response and 17 (30%) had partial responses; thus overall 18 of 57 patients achieved an objective response (32%, 95% CI 20-45). The most common treatment-emergent adverse events were diarrhoea (19 [33%] of 57 patients), fatigue (18 [32%] patients), and nausea (17 [30%] patients). Grade 3-4 treatment-emergent adverse events were recorded in 21 (37%) of 57 patients, most commonly hypokalaemia and abdominal pain (each three [5%] patients). Serious treatment-emergent adverse events were reported in ten (18%) patients and two (4%) of these adverse events (ie, chills and infusion-related reaction) were considered treatment related. There were no treatment-related deaths. INTERPRETATION: Dual HER2-targeted therapy with pertuzumab plus trastuzumab is well tolerated and could represent a therapeutic opportunity for patients with heavily pretreated, HER2-amplified metastatic colorectal cancer. FUNDING: F Hoffmann-La Roche/Genentech.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019. PMID: 30857956. doi:10.1016/S1470-2045(18)30904-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。